Researchers analyzed over 30,000 mammograms and found that specific breast texture patterns can predict cancer risk and missed diagnoses—even beyond breast density.
The FDA has approved Zynyz (retifanlimab-dlwr) as the first programmed death receptor-1 inhibitor for first-line treatment of advanced squamous cell carcinoma of the anal canal.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
A rare case of pneumomediastinum and subcutaneous emphysema following dental cleaning requires high-flow oxygen therapy rather than invasive interventions. Learn why.
In a 72-week study of hepatitis B patients, researchers found liver stiffness declines were driven by improved inflammation, not actual fibrosis regression.